Tumor antigen-specific CD8+ T cells are negatively regulated by PD-1 and Tim-3 in human gastric cancer

Cellular Immunology

Volumn 313, Issue , 2017, Pages 43-51

  Lu, Xu ^a   Yang, Lin ^b   Yao, Daxing ^c   Wu, Xuan ^a   Li, Jingpo ^a   Liu, Xuesong ^a   Deng, Lijuan ^a   Huang, Caiting ^a   Wang, Yue ^a   Li, Dan ^a   Liu, Jingwei ^a  

^a Beijing Northland Biotech Co Ltd   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

^c Department of Agricultural Science Research Institute ^*  (China)

Author keywords

CD8+ T cells; PD 1; Tim 3; Tumor associated lymphocytes

Indexed keywords

GAMMA INTERFERON; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; INTERLEUKIN 2; NY ESO 1 ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; TUMOR NECROSIS FACTOR; CTAG1B PROTEIN, HUMAN; HAVCR2 PROTEIN, HUMAN; MEMBRANE PROTEIN; PDCD1 PROTEIN, HUMAN; TUMOR ANTIGEN;

ANTIGEN SPECIFICITY; ARTICLE; CANCER PATIENT; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; IMMUNOREGULATION; LYMPHOCYTE PROLIFERATION; PERIPHERAL LYMPHOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; STOMACH CANCER; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; CANCER STAGING; CELL CULTURE; FEMALE; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOSENESCENCE; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; PATHOLOGY; STOMACH TUMOR; TUMOR ESCAPE;

ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; FEMALE; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMMUNE TOLERANCE; IMMUNOPHENOTYPING; IMMUNOSENESCENCE; LYMPHOCYTE ACTIVATION; MALE; MEMBRANE PROTEINS; NEOPLASM STAGING; PROGRAMMED CELL DEATH 1 RECEPTOR; STOMACH NEOPLASMS; TUMOR ESCAPE;

EID: 85009739567     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2017.01.001     Document Type: Article

References (25)

1. [1] Ohue, Y., Wada, H., Oka, M., et al. Antibody response to cancer/testis (CT) antigens: a prognostic marker in cancer patients. Oncoimmunology, 3, 2014, e970032.
2. [2] Matsuzaki, J., Gnjatic, S., Mhawech-Fauceglia, P., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 107 (2010), 7875–7880.
3. [3] Greenwald, R.J., Freeman, G.J., Sharpe, A.H., The B7 family revisited. Annu. Rev. Immunol. 23 (2005), 515–548.
4. [4] Saito, H., Kuroda, H., Matsunaga, T., et al. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J. Surg. Oncol. 107 (2013), 517–522.
5. [5] Dong, H., Strome, S.E., Salomao, D.R., et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8 (2002), 793–800.
6. [6] Ahmadzadeh, M., Johnson, L.A., Heemskerk, B., et al. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood 114 (2009), 1537–1544.
7. [7] Fourcade, J., Kudela, P., Sun, Z., et al. PD-1 is a regulator of NY-ESO-1-specific CD8+ T cell expansion in melanoma patients. J. Immunol. 182 (2009), 5240–5249.
8. [8] Lote, H., Cafferkey, C., Chau, I., PD-1 and PD-L1 blockade in gastrointestinal malignancies. Cancer Treat. Rev. 41 (2015), 893–903.
9. [9] Zhang, L., Wang, J., Wei, F., Profiling the dynamic expression of checkpoint molecules on cytokine-induced killer cells from non-small-cell lung cancer patients. Oncotarget, 2016.
10. [10] Yun, S.J., Jun, K.J., Komori, K., et al. The regulation of TIM-3 transcription in T cells involves c-Jun binding but not CpG methylation at the TIM-3 promoter. Mol. Immunol. 75 (2016), 60–68.
11. [11] Takano, S., Saito, H., Ikeguchi, M., An increased number of PD-1+ and Tim-3+ CD8+ T cells is involved in immune evasion in gastric cancer. Surg. Today, 2016.
12. [12] Fourcade, J., Sun, Z., Pagliano, O., et al. PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8(+) T cells induced by melanoma vaccines. Cancer Res. 74 (2014), 1045–1055.
13. [13] Odunsi, K., Qian, F., Matsuzaki, J., et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 104 (2007), 12837–12842.
14. [14] Radziewicz, H., Ibegbu, C.C., Fernandez, M.L., et al. Liver-infiltrating lymphocytes in chronic human hepatitis C virus infection display an exhausted phenotype with high levels of PD-1 and low levels of CD127 expression. J. Virol. 81 (2007), 2545–2553.
15. [15] Fourcade, J., Sun, Z., Pagliano, O., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 72 (2012), 887–896.
16. [16] Fourcade, J., Sun, Z., Benallaoua, M., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 207 (2010), 2175–2186.
17. [17] Sakuishi, K., Apetoh, L., Sullivan, J.M., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 207 (2010), 2187–2194.
18. [18] Blackburn, S.D., Shin, H., Haining, W.N., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 10 (2009), 29–37.
19. [19] Barber, D.L., Wherry, E.J., Masopust, D., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
20. [20] Kaech, S.M., Tan, J.T., Wherry, E.J., et al. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4 (2003), 1191–1198.
21. [21] Conrad, J.A., Ramalingam, R.K., Smith, R.M., et al. Dominant clonotypes within HIV-specific T cell responses are programmed death-1high and CD127low and display reduced variant cross-reactivity. J. Immunol. 186 (2011), 6871–6885.
22. [22] Penaloza-MacMaster, P., Provine, N.M., Blass, E., et al. CD4 T cell depletion substantially augments the rescue potential of PD-L1 blockade for deeply exhausted CD8 T cells. J. Immunol. 195 (2015), 1054–1063.
23. [23] Rosenblatt, J., Glotzbecker, B., Mills, H., et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine. J. Immunother. 34 (2011), 409–418.
24. [24] Zou, W., Chen, L., Inhibitory B7-family molecules in the tumour microenvironment. Nat. Rev. Immunol. 8 (2008), 467–477.
25. [25] Liu, J., Zhang, S., Hu, Y., et al. Targeting PD-1 and Tim-3 pathways to reverse CD8 T-cell exhaustion and enhance ex vivo T-cell responses to autologous dendritic/tumor vaccines. J. Immunother. 39 (2016), 171–180.